Year: 2022
Type: article
Abstract: Dedifferentiation in renal cell carcinoma (RCC), either sarcomatoid or rhabdoid, is an infrequent event that may occur heterogeneously in the setting of any RCC histology and is associated with poor outcomes. Sarcomatoid dedifferentiation is associated with inferior survival with angiogenesis targeted therapy and infrequent responses to cytotoxic chemotherapy. However, immune checkpoint therapy has significantly improved outcomes for patients with sarcomatoid dedifferentiation. Biologically, sarcomatoid dedifferentiation has increased programmed death-ligand 1 (PD-L1) expression and an inflamed tumor microenvironment, in addition to other distinct molecular alterations. Less is known about rhabdoid dedifferentiation from either a clinical, biological, or therapeutic perspective. In this focused review, we will discuss the prognostic implications, outcomes with systemic therapy, and underlying biology in RCC with either sarcomatoid or rhabdoid dedifferentiation present.
Institution: The University of Texas MD Anderson Cancer Center
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $1,700
Funders: U.S. Department of Defense, Prostate Cancer Foundation, Gateway for Cancer Research, Eli Lilly and Company, Pfizer, Exelixis, Andrew Sabin Family Foundation, Arrowhead Pharmaceuticals, Mirati Therapeutics, Calithera Biosciences, Eisai, Ono Pharmaceutical, University of Texas MD Anderson Cancer Center, National Cancer Institute
OpenAlex ID: W4296628513